cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol
1992;10:1635–1642.
Mackey JR, Baldwin SA, Young JD, Cass CE. Nucleoside transport and its significance
for anticancer drug resistance. Drug Resis Updat 1998a;1:310–324.
Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass
CE. Functional nucleoside transporters are required for gemcitabine influx and
manifestation of toxicity in cancer cell lines. Cancer Res 1998b;58:4349–4357.
Mai I, Kruger H, Budde K, Johne A, Brockmoller J, Neumayer HH, Roots I.
Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum)
with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000;38:500–
502.
Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel
Huinink WW, Schellens JH. Co-administration of GF120918 significantly increases the
systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001a;84:42–47.
Malingre MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink
WW, Schot ME, Schellens JHM. Coadministration of cyclosporine strongly
enhances the oral bioavailability of docetaxel. J Clin Oncol 2001b;19:1160–1166.
Maxwell DL, Gilmour-White SK, Hall MR. Digoxin toxicity due to interaction of
digoxin with erythromycin. BMJ 1989;298:572.
Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H,
Koopman FJ, van Tellingen O, Swart M, Schellens JHM. Coadministration of oral
cyclosporin a enables oral therapy with paclitaxel. Clin Cancer Res 1999;5:3379–
3384.
Meier PJ, Boyer JL. Preparation of basolateral (sinusoidal) and canalicular plasma
membrane vesicles for the study of hepatic transport processes. Methods Enzymol
1990;192:534–545.
Meier PJ, St. Meier-Abt A, Barrett C, Boyer JL. Mechanisms of taurocholate transport
in canalicular and basolateral rat liver plasma membrane vesicles. Evidence for an
electrogenic canalicular organic anion carrier. J Biol Chem 1984;259:10614–10622.
Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast
cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary
excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol
2005;67:1758–1764.
Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, Guyatt G. Natural health
product-drug interactions: a systematic review of clinical trials. Ther Drug Monit
2005;27:549–557.
Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN,
Linahan BM, Linsenmeyer ME, Woodcock DM. Phase I trial of cremophor EL with
bolus doxorubicin. Clin Cancer Res 1998;4:2321–2329.
Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW,
Sugiyama Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-
(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein
(BCRP1/ABCG2) knockout mice. Drug Metab Dispos 2004;32:898–901.
Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo
medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-
small-cell lung cancer. Cancer Chemother Pharmacol 2003;51:403–406.
194 DRUG TRANSPORTERS IN DRUG DISPOSITION, DRUG INTERACTIONS